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Abstract 
Soon after the discovery of the Myc gene (c-Myc), it became clear that Myc expression levels 
tightly correlate to cell proliferation. The entry in cell cycle of quiescent cells upon Myc enforced 
expression have been described in many models. Also, the downregulation or inactivation of 
Myc results in the impairment of cell cycle progression. Given the frequent deregulation of Myc 
oncogene in human cancer it is importat to dissect out the mechanisms underlying the role of 
Myc on cell cycle control. Several parallel mechanisms account for Myc-mediated stimulation of 
cell cycle. First, most of the critical positive cell cycle regulators are encoded by genes induced 
by Myc. These Myc target genes include Cdks, cyclins and E2F transcription factors. Apart from 
its direct effects on the transcription, Myc is able to hyperactivate cyclin/Cdk complexes through 
the induction of Cdk activating kinase (CAK) and Cdc25 phosphatases. Moreover, Myc 
antagonizes the activity of cell cycle inhibitors as p21 and p27 through different mechanisms. 
Thus, Myc is able to block p21 transcription or to induce Skp2, a protein involved in  p27 
degradation. Finally, Myc induces DNA replication by binding to replication origins and by 
upregulating genes encoding proteins required for replication initiation. Myc also regulates 
genes involved in the mitotic control. A promising approach to treat tumors with deregulated 
Myc is the synthetic lethality based on the inhibition of Cdks. Thus, the knowledge of the Myc-
dependent cell cycle regulatory mechanisms will help to discover new therapeutic approaches 
directed against malignancies with deregulated Myc. 
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1. Introduction. Overview of cell cycle regulation. 
Progression through the cell cycle phases (G1, S, G2 and M) is under the control of a 
family of serine/threonine protein kinases. These kinases are heterodimers consisting of a 
catalytic subunit, the cyclin-dependent protein kinase (Cdk) and a regulatory subunit, the cyclin, 
required for Cdk to be active. To date, there are 21 genes encoding Cdks and 29 genes 
encoding cyclins in the human genome [1, 2]. Of these, Cdk1, 2, 4 and 6 and A, B, E, D-type 
cyclins are identified as the major regulators of the cell cycle. The expression of the Cdks 
remains relatively constant throughout the cell cycle whereas the cyclins are synthesized and 
destroyed in a cyclical fashion during cell cycle [3, 4]. According to the “classical” cell cycle 
model (Fig. 1), at early G1-phase, mitogenic signals are first sensed and integrated by the 
expression of the D-type cyclins (D1, D2 and D3) that preferentially bind to and activate Cdk4 
and Cdk6 [1, 5]. In the late G1-phase, Cdk2 is activated by binding to E-type cyclins (E1 and 
E2). The activation of G1-phase Cdks leads to the phosphorylation of retinoblastoma protein 
(Rb) which allows the accumulation of E2F transcription factors. E2F transcriptional targets 
include genes encoding proteins required for S-phase [6, 7]. At S-phase, Cdk2 complexes with 
A-type cyclins A1 and A2. Cyclin A2 (cyclin A hereafter) is ubiquitously expressed whereas 
cyclin A1 is expressed almost exclusively during meiosis of male germline cells in the testes [8, 
9]. Cyclin A is expressed throughout the S and G2 phases and is required for DNA replication 
[10, 11]. Finally, B-type cyclins (B1 and B2) together with Cdk1 drive cells through mitosis [1, 
12]. There is also an additional cyclin B (cyclin B3), but as cyclin A1, it is only expressed in germ 
cells of testis [13, 14]. Degradation of B cyclins by the APC/C complex is required to the output 
of mitosis [11, 15].  
Nevertheless, systematic knockout of Cdk loci in the mouse germline has shown that 
Cdk2 [16, 17], Cdk4 [18, 19] and Cdk6 [20] are not essential for cell cycle progression of most 
cell types, although loss of each of these Cdks results in particular developmental defects. 
Moreover, concomitant loss of the interphase Cdk genes does not result in a general 
disturbance of the cell cycle in most cell types, being Cdk1 alone sufficient to drive the cell cycle 
progression [2, 21].   
There is also significant redundancy among cyclins genes. Cyclins D1-/-/D2-/-/D3-/- 
mouse fibroblasts proliferate normally although they require increased mitogenic stimulation for 
cell cycle re-entry [22]. Like D-cyclins, E-type cyclins are largely dispensable for cell cycle 
progression of most embryonic cells [23, 24]. However, A-type cyclins are essential for cell-
cycle progression of hematopoietic and embryonic stem cells. Only when all A- and E-type 
cyclins genes are deleted, cell division is inhibited, suggesting that both types of cyclins play 
redundant roles in cell cycle progression [25]. Finally, cyclin B1 but not B2 loss results in early 
embryonic lethality [26]. In summary, from all the cyclins that regulate the canonical cell cycle, 
cyclin A2 and B1 appear to carry out unique functions, suggesting that together with Cdk1 are 
the ‘‘basic core elements’’ of the cell-cycle machinery [27, 28]. 
Cdks are subjected to negative regulation by Cdk inhibitory proteins (CKIs). Based on 
their sequence similarity and structure, CKIs are divided into two protein families: the INK4 
(Inhibitors of Cdk4) and the CIP/KIP (Cdk Interacting Protein/Kinase Inhibitory Protein) families 
[29, 30]. The INK4 family comprises p16INK4A, p15INK4B, p18INK4C and p19INK4D. These inhibitors 
bind to free Cdk4/6 and inhibit their kinase activity, interfering with their association to D-type 
cyclins and distorting the ATP binding site. Its ectopic expression arrests the cell cycle in G1-
phase (reviewed in [29, 30]). The CIP/KIP family consists of three members: p21CIP1 (Cdk 
Interacting Protein 1), p27KIP1 (Kinase Inhibitory Protein 1) and p57KIP2 (Kinase Inhibitory Protein 
2). They bind to a broader spectrum of cyclin/Cdk complexes already formed, inhibiting their 
activities. These complexes include cyclin A-E/Cdk2, cyclin D/Cdk4-6 and cyclin A-B/Cdk1 
heterodimers. Therefore they are able to inhibit progression at every cell cycle phase.  
 Human Myc gene family is composed of MYC, MYCN and MYCL1. MYC (also called c-
MYC) encodes for Myc, which is an oncogenic transcription factor of the helix-loop-helix/leucine 
zipper protein family. Activation of transcription by Myc depends on formation of heterodimeric 
complexes with Max proteins. Myc-Max heterodimers bind to DNA sequences called E-boxes in 
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the regulatory regions of its targets genes and recruit transcriptional coactivators. However Myc 
has also the ability to repress genes although the mechanism are less well known (for recent 
reviews see [31-34]. Myc is found deregulated in nearly half of human solid tumors and 
leukemia, and appears frequently associated with tumor progression [35-37]. Although it is likely 
that the three Myc genes exert similar effects on cell cycle this review will focus on Myc, which 
is the most ubiquitously expressed of the Myc genes, the more frequently deregulated in cancer 
and, as a consequence, the most studied Myc gene with regard to the cell cycle control. 
 
2. Myc levels correlate with cell proliferation 
Soon after the discovery of Myc gene it was recognized that Myc mRNA and protein 
expression closely correlated with cell proliferation rates. This was first reported at the mRNA 
level in quiescent lymphocytes and rodent fibroblasts in which Myc mRNA underwent a rapid 
induction within 2 h after stimulation with mitogenic lectins [38-40]. Thus, Myc gene was dubbed 
as “immediate early” response gene. Later on, Myc upregulation was also described in 
response to growth factors, which occur through both transcriptional and post-transcriptional 
mechanisms [41]. Further studies showed that this induction depends on the transit from 
quiescence into the proliferative state, while in continuously cycling cells, Myc gene is 
transcribed at similar rates in all cell cycle phases, as shown in fibroblasts [42, 43].  
The mechanism for the up-regulation of Myc in quiescent cells stimulated with mitogens 
or serum is not completely known, but the data supports a relevant role for the Ras/Raf/Mek/Erk 
cascade in Myc upregulation [44]. The precise mechanism of how this cascade activates MYC 
expression remains to be established, but it likely involves the activation of transcription factors 
as Elk or Ets1-2 [45]. Myc is also upregulated upon the activation of other kinases, as reported 
for Janus kinases (Jak1 and Jak2) [46, 47], Src [48], v-Abl or Bcr-Abl [49, 50] or Akt [51, 52].  
Consistently, the response to antiproliferative cytokines as transforming growth factor β 
(TGFβ) or interferon-γ results in Myc down-regulation [53-56]. The repression of Myc by TFGβ 
is mediated by a repressive transcription factors complex of Smad4, p107 and E2F4/5 [57, 58]. 
In a parallel avenue of data, it was soon recognized that in cell culture models of differentiation, 
Myc was down-regulated as the cells undergo terminal differentiation associated to proliferation 
arrest. This was originally observed in erythroleukemia cells [59-61] and later on in other cellular 
models of different cell types (reviewed in [62]).  
 
 
3. Myc overexpression induces cell cycle progression in quiescent cells 
In agreement with the tight correlation between proliferation rates and Myc levels, the 
enforced Myc expression in quiescent cells is sufficient to mediate cell cycle entry, whereas 
inhibition of Myc expression causes cycling cells to withdraw from the cell cycle. This was 
observed in early experiments where Myc protein was transfected or microinjected into mouse 
fibroblasts [63, 64]. High Myc levels achieved upon transfection or retroviral transduction in 
cycling mammalian cells result in a reduced requirement for growth factors, block exit from the 
cell cycle, accelerate cell division, and increase cell size [65-67]. The same effects have been 
reported for Drosophila cells [68] and chick embryo cells [69]. The ectopic expression of Myc 
protein achieved by transfection or retroviral infection is able to induce S-phase in otherwise 
quiescent cells. This was elegantly confirmed using conditional Myc-estrogen receptor (MycER) 
chimeras, where Myc activation by the hormone induces cells to enter S-phase and undergo 
mitosis in the absence of external factors [70].  
Another model that demonstrates the relevant role of Myc in cell cycle is the human 
lymphoblastoid P493.6, cell line, which carries a conditional Myc allele (tet-off system) and does 
not express endogenous Myc [71]. In these cells the proliferation rates, the fraction of cells in S-
phase, and the cell size increases in a dose-dependent manner in response to increasing Myc 
levels [72]. Moreover, the genes regulated by serum stimulation and Myc were compared in this 
model and it was found that not a single Myc-induced gene was induced by serum to a similar 
extent. Thus, serum is not able to replace Myc in the regulation of proliferation-related genes 
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and viceversa [73]. Interestingly induction of Myc in the absence of serum does not result in 
proliferation but increases the cell size, protein synthesis and glycolytic metabolism, indicating 
that cell cycle progression and increase in cell size are separate effects of Myc [71].  
 
 
4. Myc downregulation impairs cell cycle progression and mitogenic response  
Consistently with the enhanced proliferation observed upon Myc overexpression, the 
downregulation or biochemical inactivation of Myc results in defective cell cycle re-entry of 
quiescent cells. Thus, Myc antisense oligonucleotides prevent S-phase entry in human 
lymphoid and myeloid cells [74, 75]. Similarly, transfection and microinjection experiments also 
show that dominant negative Myc mutants (with deletions of the N-terminal transactivation 
domain) impair the DNA synthesis induced by serum or SV40 large T antigen [76, 77].  
It was soon recognized that the decrease in Myc levels by antisense RNA results in 
slow proliferation [78]. Later on, numerous studies showed the decrease in cell proliferation rate 
upon transfection or siRNAs or short.hairpin constructs for Myc. A systematic study in 23 cell 
lines with short-hairpin-mediated depletion of Myc revealed that in normal cells and some 
tumor-derived cell lines the arrest takes place at the G0/G1 phase, but in other tumor-derived 
cell lines the arrest occurs at G2/M [79]. The reason for this difference is not clear, but it may 
depend on concomitant alterations of oncosuppressors p16, Rb or p53 in the tumor cells [79].   
An indirect proof of the role of Myc in cell cycle progression is the fact that Mxd  proteins 
(Mxd1, Mxi1, Mxd3, Mxd4 and Mnt), which bind to Myc-binding sites and antagonize Myc 
transcriptional activity, inhibit cell proliferation (reviewed in [80-82]). Cell cycle arrest is also 
observed upon the enforced expression of MadMyc, a dominant-negative Myc mutant contaning 
the DNA binding and dimerization domains of Myc and the trans-repression domain of Mxd1 
(also called Mad1). This effect is rescued by the co-expression of Myc [83, 84]. Expression of 
this mutant also abrogates the upregulation of serum-induced genes such as CCNB1 (cyclin 
B1) when starved cells are re-stimulated with serum [85]. 
Whereas all the above data indicate that a certain Myc level seems to be necessary for 
active proliferation, Myc is not strictly required for cell cycle completion, as at least some cell 
types can divide without Myc. Epiblast deletion of Myc in mouse embryos shows that Myc is not 
required for proliferation and development of most tissues in the early embryo (up to 
midgestation, E11.5) [86]. However, the effect of Myc deletion cannot be studied in cells derived 
from Myc-/- embryos as these cells are outgrown by cells overexpressing N-Myc or L-Myc. This 
problem was elegantly overcome by disruption of both Myc alleles in Rat1 fibroblasts. No mRNA 
for N-Myc or L-Myc is detected in these cells [87, 88]. These Myc-deficient cells are viable and 
do grow, although very slowly, with reduced Cdk4,6 and Cdk2 activities and with an elongated 
G1 and G2-phases [89, 90]. Similarly, Myc-deficient B lymphocytes generated by targeted 
recombination proliferate very slowly when they are mitogenically stimulated with anti-CD40 and 
IL4 [91]. Extensive screens with retroviral cDNA libraries on Myc-deficient Rat1 cells have 
revealed that only Myc and N-Myc are able to rescue the slow-growth phenotype of the cells. 
Although a particular combination of two or more genes may have passed untested in the 
screening, the data suggest that there are no functional equivalents of Myc proteins and that 
there are no Myc-activated genes that alone can substitute for Myc in control of cell proliferation 
[92].  
At least three mechanisms collaborate to explain the promoting activity of Myc in cell 
cycle progression described above: (i) transcriptional activation of genes whose products are 
required for cell cycle progression, (ii) impairment of p21 and p27 activities, and (iii) stimulation 
of DNA replication. These mechanisms will be analyzed in the next sections of this review. 
 
5. Myc target genes related to cell cycle control 
Given the Myc effects on proliferation previously mentioned, it is not surprising that cell 
cycle related genes were among the first described as “Myc target genes” (cyclin D2, cyclin E1, 
Cdk4, Cdc25A, E2F1) (reviewed in [32, 93, 94]). Prominent examples of these Myc target genes 
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as revealed in these and other studies, as well as the model where the effect is observed, are 
summarized in Table 1. The Table also shows the binding of Myc to the corresponding gene 
promoter by chromatin immunoprecipitation. The list includes pivotal cell cycle control genes as 
Cdks, cyclins and CIP/KIP proteins. Recent reports show that Myc functions as a general 
amplifier of already active genes but with low expression levels [95, 96]. However, the mRNA 
levels of some of the genes shown in Table 1 are dramatically increased upon activation of Myc 
in quiescent cells of different model systems, suggesting that Myc differentially upregulates at 
least some cell cycle control genes with respect to other genes.  
The genome-wide gene expression studies show that Myc regulates a staggering number 
of genes, around 1000 in most models [85, 97-102]. Thus, it is not surprising that many of these 
genes are related to cell cycle. In a gene expression profiling study in rat fibroblasts it has been 
shown that Myc overexpression regulated 37 out of 87 genes classified as belonging to the “cell 
cycle pathway” in the KEGG (Kyoto Encyclopedia of Genes and Genomes) [103]. In another 
study in mouse fibroblasts, about 300 genes have been identified as genes induced by serum in 
a Myc-dependent manner (i.e., not induced when Myc gene is silenced by RNA interference). 
Almost 80% of these genes have Myc bound to the promoter (i.e., in the interval ± 1kb from the 
transcription start site) [104]. This number of genes represents a small fraction (5.5% in the 
mentioned study) of all those bound by Myc, which is estimated to be  the 10-20% of all genes 
by genome-wide studies [101, 105-111]. However, the affinity of Myc for these promoters is 
higher than the mean affinity for other Myc-targeted promoters. The ontology analysis revealed 
that only a minority of genes are involved in cell cycle control, whereas the majority of the genes 
are involved in other processes, including nucleotide biosynthesis, ribosome biogenesis, DNA 
replication and RNA control [104]. It is of note that many of the Myc-target genes are involved in 
de novo nucleotide biosynthesis, protein synthesis and energetic metabolism [97, 112-115]. 
Given that the cell must duplicate its size along the cell cycle, synthesizing all cell components 
as well as all the nucleotides to be used for DNA replication, it is clear the importance of Myc in 
the biology of a cycling cell. 
Transcription factors of the E2F family are critical for G1-S progression [7, 116]. E2F1, 
E2F2, and E2F3 are induced by ectopic Myc expression in quiescent cells (Table 1) and Myc 
fails to induce S-phase in E2F2-/- or E2F3-/- cells [117, 118]. Moreover, Myc binds to E2F1-3 
promoters and the E-box in their promoters are required for full induction of E2F2 and E2F3 
expression in response to mitogens [118, 119] (Table 1). In contrast, E2F1 deficiency does not 
impair Myc-induced S-phase progression and Myc-induced tumorigenicity in vivo [117, 120]. In 
addition, E2F1 is negatively regulated by two microRNAs (miR-17 and miR-20a, from the miR-
17-92 cluster) that are induced by Myc [121, 122] suggesting a regulatory mechanism through 
which Myc simultaneously activates E2F1 transcription and limits its translation. On the other 
hand, Myc promoter contains an E2F site which is important for Myc expression [123, 124]. 
However, the E2F site on Myc promoter does not seem to bind E2F proteins but a different 
transcription factor not yet identified [125]. Therefore, the precise mechanism of the Myc-E2F 
functional interaction awaits further study.  
Besides the induction of the mir-17-92 cluster described above, Myc activity has a major 
effect as a repressor of miRNAs that target critical cell cycle regulators. These miRNAs include 
let-7 family members, miR-15a/16-1, miR-26a or miR-34a. Key cell-cycle control factors 
targeted by let-7 miRNAs include Cdc25a, Cdk6, cyclin A, cyclin D1 D2 and D3 [126-128]. miR-
34a inhibit expression of cell-cycle regulators such as Cdk4, Cdk6, cyclin E2 and E2Fs, while 
miR-15a/16-1 regulates Cdk6, E2F3, cyclin D1 and D3; and miR-26a represses cyclin D2 and 
E2 (reviewed in [127, 129]). Both induction and repression of specific miRNAs by Myc 
influences all levels of the cell cycle regulatory machinery and facilitates transit through the cell 
cycle. 
 
 
6. Myc induces Cdks activity  
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Myc-induced cell proliferation is generally associated with an increase in Cdk2, Cdk4 
and Cdk6 activities to regulate G1/S-phase progression [89, 130-132] (Fig. 1). Importantly, Myc 
is able to augment the levels of active cyclin/Cdk complexes not only through the transactivation 
of the cyclin and/or Cdk genes but also by induction of Cdk activating kinase (CAK) or 
phosphatases (Cdc25 proteins) and/or repression of a Cdk inhibitory kinase (Wee1). These 
mechanisms are described below. 
 
6.1. Cdk genes induction.  
Among all Cdk genes, CDK4 seems to be the most clear Myc target gene, as it appears 
in most gene profiling studies (Table 1). The upregulation of Cdk4 has been observed after Myc 
expression in several species (human and mouse) and cell types (endothelial cells, fibroblasts, 
B cells and epithelial cells), albeit at different degrees. The regulation of CDK4 by Myc seems to 
be direct, as suggested by the conservation of Myc binding sites in the Cdk4 promoter among 
different cell models and by the ability of Myc to activate the promoter in reporter assays [133]. 
Myc also binds to Cdk6 gene in ChIP-on-chip analysis in rat fibroblasts and Burkitt lymphoma 
cells (Daudi cells). Accordingly, Cdk6 mRNA is induced by Myc in these models, although no 
information about changes in Cdk6 protein expression have been reported [103, 108]. In 
addition, Myc binding sites to Cdk6 gene have been also identified in mouse embryonic stem 
cells [106, 107] and HeLa cells [134].  
The role of Myc in regulating Cdk2 expression is complex and there are conflicting data 
in the literature. It has been described that Myc overexpression induces Cdk2 at mRNA and 
protein level and that silencing of Myc decreases Cdk2 expression in human lung cells [135]. In 
contrast, Cdk2 expression is not affected by Myc activation in Rat1 cells [136] and no Myc 
binding to Cdk2 promoter has been described or found by the ENCODE project (ChIP-seq data 
deposited in the University of California Santa Cruz browser, http://genome.ucsc.edu/). Finally, 
Myc binding to Cdk1 promoter has been identified by ChIP in mouse embryonic stem cells [107] 
and in several human cell lines (ChIP-seq data drom ENCODE project in 
http://genome.ucsc.edu/). Intriguingly, Myc alone is not sufficient to induce the Cdk1 expression 
[137] and requires cooperation with other proteins as Ras [138] or cyclin C [137].   
 
6.2. Cyclin genes induction.  
There is some controversy about cyclin D1 regulation by Myc, and it seems to depend on 
the cell model. Myc is reported to increase cyclin D1 protein in mouse fibroblasts [139, 140] and 
rat fibroblasts (Rat1-MycER cells) [139, 141]. On the other hand, it has also been described that 
MycER activation downregulates cyclin D1 in the same Rat1-MycER cell model [132, 142]. In 
agreement with the latter result, constitutive expression of Myc also represses cyclin D1 mRNA 
in BALB/c-3T3 mouse fibroblasts [142, 143]  via core promoter elements, antagonizing USF-
mediated transactivation [143]. In other Rat1-derived cell lines, cyclin D1 expression was not 
affected by Myc expression [136, 144]. 
In contrast to the conflicting data on cyclin D1, it is stablished that cyclin D2 gene 
(CCND2) is a bona fide Myc target gene. Myc binds to the human cyclin D2 promoter in vivo via 
a single highly conserved E-box element [145, 146], induces histone acetylation in a TRRAP-
dependent manner and induces cyclin D2 mRNA and protein expression [146]. Therefore, Myc 
promotes G1-phase cell cycle progression in part through the transcriptional up-regulation of the 
cyclin D2 gene [146]. Myc also increases cyclin D2 protein in mouse fibroblasts [139, 140]. 
Cyclin D3 can be also considered a Myc target gene as it is upregulated in mouse embryo 
fibroblasts in response to Myc expression [140] and Myc binds to its promoter (Table1). 
Moreover, Myc-mediated induction of cyclin D3 has been reported in embryonic lung fibroblasts 
while Myc silencing downregulates it in lung cancer cells [135].  
Myc also upregulates cyclin E1 and E2 genes (Table 1). In rat fibroblasts, Myc activation 
induces cyclin E1 gene transcription and the increase in cyclin E1 mRNA, leading to the 
activation of cyclin E/Cdk2 complexes and induction of DNA synthesis [131]. Moreover, Myc can 
induce cyclin E1 expression indirectly through the induction of E2F transcription factors [147]. 
7 
 
Increased cyclin E2 mRNA expression has also been observed in human lung fibroblasts and 
carcinoma cells overexpressing Myc [135]. Consistently with these findings, Myc binds to cyclin 
E1 and E2 promoters in human B cells [101]. Cyclin E-type mRNA and protein have also been 
found upregulated in response to Myc activation in rat fibroblast [132, 136, 142]. In Myc-
transformed cells separated according to cell size by centrifugal elutriation, cyclin E/Cdk2 
kinase activity was upregulated not only in late G1/S, as in the normal counterparts, but 
throught the entire cell cycle [132]. Taken together the effect of Myc on Cdk4/6, Cdk2, D and E-
type cyclins, a picture emerges in which  Myc upregulates G1 cyclins/Cdks activity. The 
importance of this Myc effect is underlined by the observation that the G1 arrest induced by a 
Myc dominant-negative mutant (MadMyc, section 4) is rescued by ectopic expression of cyclin 
E/CDK2 and cyclin D1/Cdk4 [83]. 
Increased  cyclin A mRNA and protein expression is observed in Rat1 fibroblasts with 
conditional (MycER) or constitutive Myc expression [132, 136, 142, 148, 149]. Furthermore, 
cyclin A seems to be essential for Myc-dependent progression of cell cycle in human lung 
fibroblasts and  lung carcinoma cells [135]. Myc binding to CCNA2 promoter (but not to CCNA1 
promoter) is detected by ChIP-on-ChIP and ChIP-seq in several human cell lines  [134] and 
data from ENCODE project) (Table 1).  
Finally, It has been shown that Myc binds to human cyclin B1 promoter containing a 
functional Myc binding site in lung cancer cells [150]. Myc binding to cyclin B1 promoter has 
been confirmed by ChIP in HeLa cells [85]. Moreover it has been described that Myc and loss of 
p53 cooperate to induce cyclin B1 mRNA and protein in Rat1 cells and 32D myeloid cells stably 
transfected with a Myc expression vector [151].  
 
6.3. Induction of CAK activity.  
In addition to Cdk induction and cyclin binding, the complete activation of cyclin/Cdk complexes 
requires several phosphorylation and dephosphorylation events at different residues of Cdk 
proteins. Cyclin/Cdk complexes are activated by CAK (Cdk activating kinase), which 
phosphorylates the Cdk T loop [152, 153]. Thus, CAK is responsible for the activating 
phosphorylation of Thr161 in Cdk1, Thr172 in Cdk4 and Thr177 in Cdk6 which are structurally 
equivalent to Thr160 in Cdk2 [154]. CAK is composed of three subunits: Cdk7 (the catalytic 
subunit), cyclin H and MAT1. Myc increases CAK activity in rat fibroblasts increasing Cdk7, 
cyclin H, and MAT1 protein expression through augmented mRNA translation but not by Myc-
mediated transcriptional activation [155]. Nevertheless, Myc binding to CDK7 promoter has 
been shown in mouse ES cells [106] (Table 1). In agreement, Cdk7 protein expression is 
reduced in Myc-/- rat cells (HO15.19) [89, 156]. The CAK is also a subunit of TFIIH, one of the 
general transcription factors present in the RNA polymerase II preinitiation complex [154]. Myc 
recruits Cdk7 to the transcriptional start site, increases CAK activity and the concomitant 
phosphorylation on Ser5 of the C-terminal domain (CTD) of RNA polymerase II, a 
phosphorylation associated to initiation of transcription [155, 157].  
 
6.4. Induction of Cdc25 phosphatases.  
Cdks can also be regulated via inhibitory phosphorylations of two conserved residues near the 
N-terminus (Thr14 and Tyr15 in human Cdk1 and Cdk2) located within the ATP-binding site of 
the enzyme [153]. Tyr15 phosphorylation is carried out by Wee1 [158]. It has been described 
that both Myc [159] and N-Myc [160] induce miR-221, which has been shown to target Wee1 
[161]. Thus, it is likely that Myc can repress Wee1 by induction of this microRNA, although 
further studies are required to confirm this hypothesis. miR-221 also affects multiple cancer 
pathways by modulating other mRNAs, including inhibition of Rb, p27 and p57 [161, 162]. 
Dephosphorylation of both residues are required for Cdk activation and cell cycle regulation, 
particularly at mitosis for the control of Cdk1 activation, and this is carried out by dual specific 
phosphatases of the Cdc25 family [152, 153]. Cdc25A has been proposed to be a Myc target 
gene [163] although no changes in Cdc25A mRNA or protein have been observed following 
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Myc-ER activation in quiescent Rat1-fibroblasts and Cdc25A gene expression was unaffected in 
Myc-/- cells [88, 131, 132].  
 
 
7. Myc and p21CIP1   
As mentioned before, Myc represses the cyclin-dependent kinase inhibitor p21CIP1/Waf1 
(p21 hereafter). One of the first evidences came from human immortalized keratinocyte cells 
stably expressing Myc, where Myc inhibited TGFβ-mediated repression of cell-cycle progression 
abolishing the induction of p21 expression [164]. Several mechanisms are used by Myc to 
repress p21 and are summarized in Fig. 2A. The most studied mechanism for Myc-mediated 
repression of p21 is through the initiator-binding transcription factor Miz-1. While Miz-1 
stimulates transcription, the direct interaction with Myc transform this zinc-finger transcription 
factor into a transcriptional repressor [165, 166]. This interaction blocks p21 induction by p53 
and, as a consequence, Myc contributes to the initiation of apoptosis by p53 [167]. Moreover, 
through this mechanism Myc also blocks the p21-mediated differentiation of hematopoietic cells 
[168]. Furthermore, it has been described that Myc and Miz-1 form a ternary complex with the 
DNA methyltransferase DMNT3a and that DNA methylation is required for Myc-mediated 
repression of CDKN1A (p21). This suggest that Myc can silence  p21 gene expression not only 
by passive Miz-1 functional interference but also by active recruitment of corepressor proteins 
[169].  
There are additional mechanisms which allows Myc to repress p21 (Fig. 2A): (i) Myc 
triggers a transcriptional cascade by inducing the gene encoding the transcription factor AP4 
(TFAP4), which binds to recognition motifs in the p21 promoter and mediates transcriptional 
repression of p21 [170]. (ii) Myc antagonized the induction of p21 mediated by oncogenic Ras 
[171]. p21 upregulation by Ras depends on SP1 and Myc interferes with SP1 transactivation of 
p21 promoter [171, 172].  (iii) Myc interacts with the histone demethylase KDM5B and with the 
transcription factor TFAP2C (AP2-gamma) forming a ternary complex that repress p21 
transcription [173]. This implies a histone H3 demethylation mechanism for p21 repression. 
Therefore, both histone demethylation and DNA methylation seems to be required for Myc-
mediated repression of p21. (iv) Finally, Myc induces the microRNA cluster miR-17-92, which 
includes miRNAs predicted to target p21 mRNA [159, 174, 175]. 
 
 
8. Myc and p27KIP1   
One of the most important targets of Myc in cell proliferation is the Cdk inhibitor p27. 
Myc accelerates cell proliferation rates, at least in part, through its ability to antagonize p27 
activities in proliferation and differentiation [176, 177]. Accordingly, Myc-deficient cells show 
increased p27 protein levels [89, 91]. This is accomplished by several parallel mechanisms, 
summarized  in Fig. 2B: (i) Myc suppresses p27 expression at transcriptional level in lymphoid 
and breast cancer cells [178, 179] (Table 1). (ii) Myc induces de miR-221 and miR-222 that 
leads to p27 mRNA silencing [159, 162]. Previous experiments have showed that miR-221 is 
able to induce proliferation targeting p27, both in vitro [162] and in vivo [180]. (iii) Myc induces 
cyclin E transcription directly or through the induction of E2F transcription factors, increasing the 
levels of cyclin E/Cdk2 complexes that functionally antagonize p27 by promoting G1/S 
transition.[130, 131, 176] (iv) Induction of cyclins D1 and D2, as well as their catalytic partners 
Cdk4 and Cdk6 by Myc, allows the assembly of cyclin D/Cdk4,6 complexes, which sequester 
p27 and relieve the inhibition of cyclin E/Cdk2 complexes [145, 181, 182]. (v) Myc induces the 
expression of several components of the SCFSKP2 ubiquitin ligase complex, the major complex 
that ubiquitinates p27. Thus, Myc induces Cul1 [183], Cks1 [184] and the F-box protein Skp2, 
the subunit involved in substrate selection and that recognizes Thr187-phosphorylated p27 
[185]. This phosphorylation is required for p27 degradation by the proteasome [186-189]. 
Interestingly, Myc also stimulates the Thr187 phosphorylation of p27, likely through the 
upregulation of Cyclin E/Cdk2 [185, 190]. Since SCFSKP2 is the most important ubiquitin ligase 
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for p27 degradation [191, 192], Myc appears to be a major regulator of p27 levels in cell nuclei.  
The general picture describes Myc as a potent inhibitor of p27 activity as cell cycle brake. This 
is important given that p27 expression is frequently downregulated in human cancer and low 
p27 levels associate to poor prognosis [193, 194]. However, impairment of p21 and p27 function 
is not the only pro-proliferative mechanism elicited by Myc, as mouse embryo fibroblasts 
deficient for both p27 and the related p21 are still responsive to stimulation by Myc and can be 
arrested in G1 by a dominant negative mutant of Myc [195]. 
 
 
9. Myc, DNA replication and mitosis  
Myc induces genes directly related to DNA replication. The origin recognition complex 
(ORC) is a highly conserved six subunits protein complex essential for the initiation of the DNA 
replication in eukaryotic cells. A number of ORC genes as ORC1, ORC2, ORC4 and ORC5 
have been identified as Myc targets in mouse fibroblasts and human B cells [101, 103]. The 
gene encoding for Cdc6 (Cell Division Cycle 6), a protein required for the initiation of replication, 
has also been found to be a Myc target gene [101, 108]. Myc also induces genes encoding 
MCM (minichromosome maintenance) proteins as MCM3, MCM4 and MCM5 [101, 105, 108], 
which are essential for correct DNA replication initiation and elongation. Besides the gene 
expression induction described above, it has been also reported that Myc stimulates DNA 
replication independently of transcription. The initial observation was the inhibition of the 
replication of episomal DNA by anti-Myc antibodies [196]. Later on, it was shown that Myc 
stimulates DNA replication in a transcriptional-independent manner. Myc interacts with the pre-
replicative complex and localizes to origins of DNA replication in mammalian cells and in 
Xenopus cell-free extracts. Myc depletion provokes a slow replication due to defective 
replication initiation once the pre-replicative complexes are assembled [197]. Myc 
overexpression initiates premature origin firing and increases origin density, and leads to 
asymmetrical fork progression [197, 198]. Thus, this mechanism explains that, when 
deregulated, Myc generates DNA replication stress and DNA damage, an observation made in 
several models [199-202]. Also, high Myc levels enhance re-replication of DNA in the p21-
induced polyploidization process of myeloid cells [203]. However, it is unclear whether this non-
transcriptional Myc activity on replication contributes to the DNA replication in the S-phase of 
cells with physiological Myc levels.  Last but not least, Myc activates the transcription of human 
telomerase (TERT), which may contribute to sustain the proliferation of tumor cells along the 
cell cycle [204, 205]. 
Finally, not only  Cdk1 and mitotic cyclins, but some genes encoding proteins required 
for mitosis are also regulated by Myc. The anaphase promoting complex/cyclosome (APC/C) is 
a multisubunit E3 ubiquitin ligase required for mitotic progression by targeting for destruction 
key mitotic regulators such as cyclin B1 and securin, the separase inhibitor required for the 
correct anaphase [206, 207]. Myc induce the genes encoding three subunits of APC/C: Anapc5, 
Cdc16 and Cdc23 [103] and binds their promoter in mouse embryonic stem (ES) cells and 
human myeloid cells ([107] and ENCODE project, http://genome.ucsc.edu/). Myc would not only 
promote securin degradation through upregulation of APC/C sununits but also repress the 
securin gene (Pttg1) [103], suggesting a major role in mitotic control. On the other hand, it has 
also been reported that Myc represses Anapc2 (another component of the APC/C complex) and 
Cdc20, the APC/C coactivator [103]. Moreover, Myc also activates the expression of human 
BubR1 and Mad2 genes, two APC/C repressors, delaying prometaphase [208]. The effects  of 
Myc on mitotic progression are not well understood yet,  although the Myc-mediated induction of 
some of these regulators (e.g, BubR1 and Mad2) has been related to the chromosomal 
instability elicited by deregulated Myc [208-210] 
 
 
10. Conclusion and remarks 
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We have reviewed here the many functions of Myc related to the cell cycle regulation. 
From the pioneering studies in the 1980’s to the genome-wide studies today, the general picture 
shows that control of cell proliferation is one of the major roles of Myc in cell biology. The bulk of 
data shows that Myc overexpression stimulates whereas Myc downregulation inhibits cell cycle 
progression. Several mechanisms by which Myc influences the cell cycle have been elucidated. 
Most of them are related to the Myc-mediated induction or repression of target genes encoding 
positive or negative cell cycle regulators, respectively. However, there are still many unclear 
aspects of these mechanisms. The stimulation of cell cycle progression is likely the most 
relevant activity –albeit not the only one – for the oncogenic activity of Myc. Given the frequent 
deregulation of Myc oncogene observed in many human tumours it is of crucial importance to 
further decipher the molecular mechanisms underlying the role of Myc on the regulation of the 
cell cycle. Although Myc is not an easily druggable target, a promising approach to deal with 
tumors with deregulated Myc is the synthetic lethality based on the inhibition of Cdks. In this 
line, it has been described synthetic-lethal interaction between Myc and Cdk1 in lymphoma, 
liver cancer and breast cancer [211, 212]. The effort to elucidate the Myc-dependent cell cycle 
regulatory mechanisms would eventually help to discover new therapeutic approaches directed 
against malignancies with deregulated Myc. 
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Table 1. Myc target genes involved in cell cycle. ChIP, chromatin immunoprecipitation; ChIP-on-
chip, ChIP followed by analysis by chip microarray of the immunoprecipitated chromatin/DNA; 
ChIP-seq, ChIP followed by sequencing of the immunoprecipitated chromatin/DNA ChIP-PET, 
ChiP coupled with pair-ends tag sequencing. Human gene nomenclatura is used.  
 
Target 
gene 
Myc effect 
on 
expression 
Cells  
Myc bound to promoter  
Method / Cells 
CCND1 
(Cyclin D1) 
Induced Rodent fibroblasts [139-141] 
ChIP-on-ChIP / mouse ES cells [107] 
Repressed Rodent fibroblasts [132, 142, 143, 213] 
CCND2 
(Cyclin D2) 
Induced 
 
Rodent fibroblasts [139, 140, 145, 146] 
Human primary fibroblasts [99] 
  
Reporter assays / mouse fibroblasts 
[145] 
ChIP / mouse fibroblasts and human 
myeloid cells (HL60) [146]  
ChIP-PET / human B cells (P493.6) [101] 
CCND3 
(Cyclin D3) 
Induced 
Mouse embryonic fibroblasts [140] 
Human embryonic lung fibroblasts and human 
lung carcinoma epithelial cells [135] 
ChIP-PET / human B cells (P493.6) [101] 
CCNE1 
(Cyclin E1) 
Induced Rat fibroblasts [103, 131] ChIP-PET / human B cells (P493.6) [101] 
CCNE2 
(Cyclin E2) 
Induced 
Human embryonic lung fibroblasts (HEL) and 
human lung carcinoma epithelial cells (A549) 
[135] 
ChIP-PET / human B cells (P493.6) [101] 
ChIP-on-ChIP / human cervical 
carcinoma cells (HeLa) [134] 
ChIP-on-ChIP / mouse ES cells [107] 
CCNA2 
(Cyclin A) 
Induced 
Rat fibroblasts [132, 136, 142, 148, 149] 
Human embryonic lung fibroblasts (HEL) and 
human lung carcinoma epithelial cells (A549) 
[135] 
ChIP-on-ChIP / human HeLa cells [134] 
CCNB1 
(cyclin B1) 
Induced 
Mouse myeloid cells (32D) and rat fibroblasts  
[151] 
Human umbilical vein endothelial cells (HUVEC) 
[85] and human lung cancer cells (NCI-H460) 
[150] 
ChIP/ human lung cancer cells [150] 
ChIP and ChIP-on-ChIP / Human HeLa 
cells [85, 134] 
ChIP-on-ChIP / mouse ES cells [107] 
CDK1  Induced 
Mouse pro-B cells (BAF-B03) [137]  
Rat fibroblast [138, 213] 
ChIP-on-ChIP / mouse ES cells [107] 
CDK2 
Induced 
Human embryonic lung fibroblasts (HEL) and 
human lung carcinoma epithelial cells (A549) 
[135] - 
Repressed Rat fibroblasts [103] 
CDK4 Induced 
Rodent fibroblasts [103, 104, 133, 213, 214] 
Human umbilical vein endothelial cells (HUVEC) 
[85, 133] 
 
ChIP-PET / human B cells (P493.6) [101] 
ChIP and ChIP-on-ChIP/ human cervical 
carcinoma cells (HeLa)  [85, 134] 
ChIP-seq / human Burkitt lymphoma 
cells (Raji, CA46, Blue1,BL41 and 
Ramos) [111] 
ChIP-on-ChIP and ChIP-seq / mouse ES 
cells [95, 106] 
ChIP-seq / mouse fibroblast [104] 
CDK6 Induced Rat fibroblasts [103] 
ChIP-on-ChIP / human Burkitt lymphoma 
cells (Daudi) [108] 
ChIP-on-ChIP / human cervical 
carcinoma cells (HeLa) [134] 
ChIP-on-ChIP / mouse ES cells [106, 
107] 
CDK7 Induced 
Human epithelial cells [155] and rat fibroblasts 
[89, 155, 156]. 
ChIP-on-ChIP and ChIP-seq / Mouse ES 
cells [95, 106, 107] 
CDC25A Induced Rodent fibroblats [103, 163]  
ChIP-on-ChIP/ human cervical 
carcinoma cells (HeLa) [134] 
E2F1 Induced Mouse B cells [184] and rat fibroblast [118, 215] 
ChIP / human myeloid cells (U-937 and 
HL60), human B cells (P493.6), human 
glioblastoma (T98G), human skin 
fibroblasts (WS1) [105] 
 
E2F2 
Repressed Rat fibroblast [103] 
ChIP-Seq, ENCODE project, 
(http://genome.ucsc.edu/) 
Induced Rat fibroblasts [119]  
E2F3 Induced Rat fibroblasts [103, 118] ChIP-on-ChIP / mouse ES cells [107] 
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CDKN1A 
(p21) 
Repressed 
 
Mouse fibroblast [104, 164] 
Human primary fibroblasts (WI-38) [99]; human 
embryonic lung fibroblasts (HEL) and human 
lung carcinoma epithelial cells (A549) [135]; 
human keratinocytes [164]; human colon 
carcinoma cells (HCT116) [167] and human 
myeloid cell lines (U-937, HL60 and K562) [168]  
ChIP/ rat fibroblasts [216] 
ChIP / human myeloid cells (U-937 and 
HL60) [168] 
ChIP-PET / human B cells (P493.6) [101] 
ChIP-on-ChIP / human cervical 
carcinoma cells (HeLa) [134] 
CDKN1B 
(p27) 
Repressed  
 Mouse B cells (WEHI 231) [178, 217] 
Rat fibroblasts [103] 
Human T cells (Jurkat) and human breast cancer 
cells (Hs578T) [178]; human embryonic lung 
fibroblasts (HEL) and human lung carcinoma 
epithelial cells (A549) [135] 
Reporter assays / human T cells (Jurkat) 
[178] 
ChIP-on-ChIP/ human Burkitt lymphoma 
cells (Daudi) [108] 
 
CDKN2B 
(p15) 
Repressed 
Rat [218] and mouse fibroblasts [104] 
Human keratinocytes [219] 
ChIP / human myeloid cells (HL60) and 
rat fibroblasts [216] 
ChIP-PET/ human B cells (P493.6) [101] 
 
 
 
 
 
 
 
 
Figure Legends 
 
Figure 1. Myc stimulates the cell cycle progression. 
Schematic representation of the cell cycle phases, the main cell cycle regulators and how Myc 
influence the cell cycle through the induction or repression of target genes encoding many of 
those regulators. The cell cycle progression is mainly regulated by the sequential action of 
cyclin-Cdk complexes that induce the correct progression through the cell cycle phases.  
Activated Cdks phosphorylate different substrates including the retinoblastoma protein (Rb). 
Such mechanism allows the activation of the E2F transcription factors which transactivate target 
genes related to DNA synthesis. Different Cdk inhibitors such as p15, p16, p21 or p27 inhibit 
cyclin-Cdk complexes. Myc induces the expression of several positive regulators of the cell 
cycle while represses cell cycle inhibitors by different mechanisms (see text for details). As a 
consequence, Myc stimulates the cell cycle progression and the cellular proliferation.  
 
Figure 2. Mechanisms for Myc-mediated antagonism of p21 (A) and p27 (B). Myc stimulates 
cell proliferation through its ability to antagonize p21 and p27 expression and activities. This is 
accomplished by different direct and indirect mechanisms, as schematized in the figure. See 
Sections 7 and 8 for details  
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